CenTrial Logo

DELIVER Trial explores the Efficacy of Eptinezumab in Migraine Prevention


Clinical trial finds eptinezumab effective in preventing migraine

Migraines can interfere with your daily life and make it difficult to do the things you love. That's why researchers are constantly looking for new ways to prevent migraines.
In a clinical trial, scientists tested the safety and effectiveness of a new drug called eptinezumab in patients who had tried and failed two to four other migraine treatments.

What is Migraine?

Migraine is a common health condition, affecting around 1 in every 5 women and around 1 in every 15 men. It is defined as a moderate or severe headache felt as a throbbing pain on 1 side of the head. Many people may also have symptoms such as feeling sick, being sick, and increased sensitivity to light or sound during a migraine attack. Some individuals may also have an aura before the headache where there are specific warning signs just before the migraine begins, such as seeing flashing lights.

There is no cure for migraine but there are medications to manage the symptoms and prevent further attacks. Eptinezumab is one such drug that has shown potential benefit in preventing migraines but its effect in patients with previous treatment failures is unknown.

Clinical Trial

A clinical trial tested the effectiveness of eptinezumab for migraine prevention in patients with multiple treatment failures in the past.

The trial, called DELIVER,  was a phase 3b trial that included 891 patients who had episodic or chronic migraine with at least 4 monthly migraine days (as per International Headache Society guidelines) and documented evidence of two-to-four previous preventive treatment failures within the past 10 years.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me
These patients were divided into three groups according to the treatment they were set to receive: eptinezumab 100 mg, eptinezumab 300 mg, or placebo. The researchers measured the change in the average monthly migraine days in all three groups.


The results of the clinical trial showed that eptinezumab was effective in reducing the number of migraines that patients experienced each month. Patients who received eptinezumab 100mg had, on average, 4.8 fewer migraine days per month compared to the eptinezumab 300mg group which had 5.3 fewer migraine days, and the placebo group which had 2.1 fewer migraine days.

Additionally, treatment-emergent adverse events occurred in 127 (42%) of 299 patients in the eptinezumab 100 mg group, in 120 (41%) of 294 in the eptinezumab 300 mg group, and in 119 (40%) of 298 in the placebo group. The most common adverse event was COVID-19. However, serious adverse events were uncommon occurring in only 2% of the patients in eptinezumab groups.


The DELIVER clinical trial provides important information about the safety and effectiveness of eptinezumab for migraine prevention. It suggests that eptinezumab can be a valuable tool for those who suffer from frequent migraines and have not found relief with other treatments.

If you suffer from migraines and have not found relief with other treatments, you may want to talk to your doctor about whether eptinezumab could be a good option for you.
The Lancet Neurology, Jul-22
ClinicalTrials.gov  NCT04418765

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Without participants there can be no clinical trials.
Without clinical trials there will be no new treatments.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.